Cytoglobin promotes sensitivity to ferroptosis by regulating p53-YAP1 axis in colon cancer cells.
Adaptor Proteins, Signal Transducing
/ metabolism
Carbolines
/ toxicity
Colonic Neoplasms
/ genetics
Cytoglobin
/ genetics
Ferroptosis
HCT116 Cells
Humans
Piperazines
/ toxicity
Reactive Oxygen Species
/ metabolism
Signal Transduction
Transcription Factors
/ metabolism
Tumor Suppressor Protein p53
/ metabolism
Up-Regulation
YAP-Signaling Proteins
YAP1
colon cancer
cytoglobin
ferroptosis
lipid peroxidation
p53
Journal
Journal of cellular and molecular medicine
ISSN: 1582-4934
Titre abrégé: J Cell Mol Med
Pays: England
ID NLM: 101083777
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
revised:
22
01
2021
received:
19
10
2020
accepted:
08
02
2021
pubmed:
22
2
2021
medline:
18
9
2021
entrez:
21
2
2021
Statut:
ppublish
Résumé
Ferroptosis is an iron-dependent mode of non-apoptotic cell death characterized by accumulation of lipid reactive oxygen species (ROS). As a regulator of ROS, cytoglobin (CYGB) plays an important role in oxygen homeostasis and acts as a tumour suppressor. However, the mechanism by which CYGB regulates cell death is largely unknown. Here, we show that CYGB overexpression increased ROS accumulation and disrupted mitochondrial function as determined by the oxygen consumption rate and membrane potential. Importantly, ferroptotic features with accumulated lipid ROS and malondialdehyde were observed in CYGB-overexpressing colorectal cancer cells. Moreover, CYGB significantly increased the sensitivity of cancer cells to RSL3- and erastin-induced ferroptotic cell death. Mechanically, both YAP1 and p53 were significantly increased based on the RNA sequencing. The knock-down of YAP1 alleviated production of lipid ROS and sensitivity to ferroptosis in CYGB overexpressed cells. Furthermore, YAP1 was identified to be inhibited by p53 knock-down. Finally, high expression level of CYGB had the close correlation with key genes YAP1 and ACSL4 in ferroptosis pathway in colon cancer based on analysis from TCGA data. Collectively, our results demonstrated a novel tumour suppressor role of CYGB through p53-YAP1 axis in regulating ferroptosis and suggested a potential therapeutic approach for colon cancer.
Identifiants
pubmed: 33611811
doi: 10.1111/jcmm.16400
pmc: PMC8034452
doi:
Substances chimiques
Adaptor Proteins, Signal Transducing
0
CYGB protein, human
0
Carbolines
0
Cytoglobin
0
Piperazines
0
RSL3 compound
0
Reactive Oxygen Species
0
TP53 protein, human
0
Transcription Factors
0
Tumor Suppressor Protein p53
0
YAP-Signaling Proteins
0
YAP1 protein, human
0
erastin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
3300-3311Subventions
Organisme : Natural Science Foundation of Ningbo
ID : 2019A610325
Organisme : Zhejiang Provincial Natural Science Foundation of China
ID : LY17C060002
Organisme : Zhejiang Provincial Natural Science Foundation of China
ID : Y21C060006
Informations de copyright
© 2021 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.
Références
Adv Mater. 2019 Dec;31(51):e1904197
pubmed: 31595562
Hum Mol Genet. 2006 Jul 1;15(13):2038-44
pubmed: 16698880
Am J Pathol. 2015 Apr;185(4):1045-60
pubmed: 25665792
Nat Cell Biol. 2013 Jun;15(6):637-46
pubmed: 23708000
Curr Opin Pharmacol. 2016 Aug;29:26-33
pubmed: 27262779
Nature. 2019 Aug;572(7769):402-406
pubmed: 31341276
Nature. 2015 Apr 2;520(7545):57-62
pubmed: 25799988
Nat Cell Biol. 2018 Oct;20(10):1104-1105
pubmed: 30224762
Cell. 2012 May 25;149(5):1060-72
pubmed: 22632970
J Cell Mol Med. 2019 Aug;23(8):4900-4912
pubmed: 31232522
Cancer Commun (Lond). 2018 Apr 25;38(1):12
pubmed: 29764521
Curr Opin Cell Biol. 2017 Dec;49:99-107
pubmed: 29316535
Mol Biol Evol. 2002 Apr;19(4):416-21
pubmed: 11919282
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Nature. 2011 Jun 08;474(7350):179-83
pubmed: 21654799
Nucleic Acids Res. 2015 Apr 20;43(7):e47
pubmed: 25605792
Cell Rep. 2019 Sep 3;28(10):2501-2508.e4
pubmed: 31484063
CA Cancer J Clin. 2019 Jan;69(1):7-34
pubmed: 30620402
J Biol Chem. 2001 Jul 6;276(27):25318-23
pubmed: 11320098
Cell. 2014 Jan 16;156(1-2):317-331
pubmed: 24439385
Hum Mol Genet. 2013 Aug 15;22(16):3207-17
pubmed: 23591990
Front Cell Dev Biol. 2019 Aug 09;7:159
pubmed: 31448276
Sci Rep. 2016 May 05;6:24990
pubmed: 27146058
Nature. 2017 Nov 9;551(7679):247-250
pubmed: 29088702
Am J Pathol. 2011 Jan;178(1):128-39
pubmed: 21224051
J Cell Mol Med. 2021 Apr;25(7):3300-3311
pubmed: 33611811
EMBO Rep. 2014 Jun;15(6):642-56
pubmed: 24825474
Cancer Cell. 2016 Jun 13;29(6):783-803
pubmed: 27300434
Cell. 2017 Oct 5;171(2):273-285
pubmed: 28985560
Am J Pathol. 2011 Aug;179(2):1050-60
pubmed: 21684245
Nat Med. 2014 Jun;20(6):599-606
pubmed: 24813251
Cancer Cell. 2019 Jun 10;35(6):830-849
pubmed: 31105042
Proc Jpn Acad Ser B Phys Biol Sci. 2016;92(3):77-97
pubmed: 26972599
Cancer Cell. 2017 Jan 9;31(1):50-63
pubmed: 28073004
Nature. 2017 Jul 27;547(7664):453-457
pubmed: 28678785
Cancer Res. 2017 Nov 1;77(21):5769-5781
pubmed: 28916653
Mol Cell. 2019 Jan 17;73(2):354-363.e3
pubmed: 30581146
CA Cancer J Clin. 2020 May;70(3):145-164
pubmed: 32133645
Cancer Biol Ther. 2013 Jun;14(6):511-20
pubmed: 23760493
Cell Death Differ. 2008 Nov;15(11):1752-9
pubmed: 18617895